Artículos por temáticas

Validation of the Italian version of carers' quality-of-life questionnaire for parkinsonism (PQoL Carer) in progressive supranuclear palsy.

Picillo M, Cuoco S, Amboni M, Bonifacio FP, Bruno A, Bruschi F, Cappiello A, De Micco R, De Rosa A, Di Biasio F, Elifani F, Erro R, Fabbri M, Falla M, Franco G, Frosini D, Galantucci S, Lazzeri G, Mag

Neurol Sci. 2019 Jun 12. doi: 10.1007/s10072-019-03944-x. [Epub ahead of print]

Quality of life predicts outcome of deep brain stimulation in early Parkinson disease.

[No authors listed]

Neurology. 2019 Jun 11;92(24):1166. doi: 10.1212/WNL.0000000000007420. No abstract available.

Gait stride-to-stride variability and foot clearance pattern analysis in Idiopathic Parkinson's Disease and Vascular Parkinsonism.

Ferreira F, Gago MF, Bicho E, Carvalho C, Mollaei N, Rodrigues L, Sousa N, Rodrigues PP, Ferreira C, Gama J.

J Biomech. 2019 May 30. pii: S0021-9290(19)30383-5. doi: 10.1016/j.jbiomech.2019.05.039. [Epub ahead of print]

Parkinsonism in essential tremor cases: A clinicopathological study.

Rajput AH, Rajput EF, Bocking SM, Auer RN, Rajput A.

Mov Disord. 2019 Jun 10. doi: 10.1002/mds.27729. [Epub ahead of print]

Mitochondrial and autophagic alterations in skin fibroblasts from Parkinson disease patients with Parkin mutations.

González-Casacuberta I, Juárez-Flores DL, Ezquerra M, Fucho R, Catalán-García M, Guitart-Mampel M, Tobías E, García-Ruiz C, Fernández-Checa JC, Tolosa E, Martí MJ, Grau JM, Fernández-Santiago R, Carde

Aging (Albany NY). 2019 Jun 9;11(11):3750-3767. doi: 10.18632/aging.102014.

Lower volume, more impairment: reduced cholinergic basal forebrain grey matter density is associated with impaired cognition in Parkinson disease.

Barrett MJ, Sperling SA, Blair JC, Freeman CS, Flanigan JL, Smolkin ME, Manning CA, Druzgal TJ.

J Neurol Neurosurg Psychiatry. 2019 Jun 7. pii: jnnp-2019-320450. doi: 10.1136/jnnp-2019-320450. [Epub ahead of print]

Pain characteristics and its relationship with motor dysfunction in individuals with parkinson disease - a cross-sectional study.

de Mattos DC, Meziat Filho NA, Pedron CA, Vasconcellos LF, Nogueira LAC, de Oliveira LAS.

Pain Pract. 2019 Jun 7. doi: 10.1111/papr.12803. [Epub ahead of print]

Association of Antiviral Therapy With Risk of Parkinson Disease in Patients With Chronic Hepatitis C Virus Infection.

Lin WY, Lin MS, Weng YH, Yeh TH, Lin YS, Fong PY, Wu YR, Lu CS, Chen RS, Huang YZ.

JAMA Neurol. 2019 Jun 5. doi: 10.1001/jamaneurol.2019.1368. [Epub ahead of print]

Is Interferon Therapy for Hepatitis C Infection a Treatable Risk Factor for Parkinson Disease?

Ramirez-Zamora A, Hess CW, Nelson DR.

JAMA Neurol. 2019 Jun 5. doi: 10.1001/jamaneurol.2019.1377. [Epub ahead of print] No abstract available.

Pearls & Oy-sters: CAA-related inflammation presents as subacute cognitive decline in a patient with Parkinson disease.

Gera A, Witek N, Bailey M.

Neurology. 2019 Jun 4;92(23):1116-1118. doi: 10.1212/WNL.0000000000007610. No abstract available.

Prospective cohort study of patients with early gastric cancer to detect prodromal Parkinson disease (EGC-PPD): A study protocol and baseline characteristics.

Shin C, Yang HK, Park S, Lee HJ, Kong SH, Suh YS, Huh YJ, Kim YJ, Park SY, Ahn TB, Lee SH, Kim HJ, Jeon B.

J Clin Neurosci. 2019 May 29. pii: S0967-5868(19)30550-8. doi: 10.1016/j.jocn.2019.05.033. [Epub ahead of print]

Prodromal Parkinson disease: do we miss the signs?

Postuma RB.

Nat Rev Neurol. 2019 May 31. doi: 10.1038/s41582-019-0215-z. [Epub ahead of print] No abstract available.

Systematic review of the pharmacoeconomics of Parkinson disease medications.

Wang AS, Gunzler S.

Expert Opin Pharmacother. 2019 May 31:1-12. doi: 10.1080/14656566.2019.1622091. [Epub ahead of print]

Dopamine drives binge-like consumption of a palatable food in experimental Parkinsonism.

Mineo D, Cacace F, Mancini M, Vannelli A, Campanelli F, Natale G, Marino G, Cardinale A, Calabresi P, Picconi B, Ghiglieri V.

Mov Disord. 2019 Jun;34(6):821-831. doi: 10.1002/mds.27683. Epub 2019 Apr 19.

Baicalein enhances the effect of low dose Levodopa on the gait deficits and protects dopaminergic neurons in experimental Parkinsonism.

Zheng ZV, Cheung CY, Lyu H, Chan HY, Li Y, Bian ZX, Wang KKW, Poon WS.

J Clin Neurosci. 2019 Jun;64:242-251. doi: 10.1016/j.jocn.2019.02.005. Epub 2019 Mar 21.